TABLE 5.
Antimicrobial susceptibility of the most prevalent REA groups 2011 to 2016
| Antibiotic | REA group | MIC range (μg/ml) | MIC50 (μg/ml) | MIC90 (μg/ml) | % Resistant |
|
|---|---|---|---|---|---|---|
| CLSI | EUCAST | |||||
| Fidaxomicin | BI [188] | ≤0.004–1 | 0.25 | 0.5 | NA | NA |
| All non-BI types [850]a | ≤0.004–1 | 0.25 | 0.5 | NA | NA | |
| A [42] | ≤0.004–1 | 0.25 | 0.5 | NA | NA | |
| DH [126] | 0.03–1 | 0.25 | 0.5 | NA | NA | |
| G [59] | 0.008–1 | 0.25 | 0.5 | NA | NA | |
| Y [163] | ≤0.004–0.5 | 0.25 | 0.5 | NA | NA | |
| Rifaximin | BI | ≤0.004 to >4 | 0.03 | >4 | NA | NA |
| All non-BI types | ≤0.004 to >4 | 0.015 | 0.03 | NA | NA | |
| A | ≤0.004 to >4 | 0.03 | 0.06 | NA | NA | |
| DH | 0.008 to >4 | 0.03 | 0.03 | NA | NA | |
| G | ≤0.004 to >4 | 0.03 | 0.03 | NA | NA | |
| Y | ≤0.004 to >4 | 0.015 | 0.03 | NA | NA | |
| Rifampin | BI | ≤0.004 to >4 | 0.008 | >4 | NA | 74.5 |
| All non-BI types | ≤0.004 to >4 | ≤ 0.004 | 0.008 | NA | 35.3 | |
| A | ≤0.004 to >4 | ≤ 0.004 | 0.008 | NA | 33.3 | |
| DH | ≤0.004 to >4 | ≤ 0.004 | 0.008 | NA | 49.2 | |
| G | ≤0.004–4 | ≤ 0.004 | 0.008 | NA | 25.4 | |
| Y | ≤0.004 to >4 | ≤ 0.004 | 0.008 | NA | 35.0 | |
| Tigecycline | BI | ≤0.06–0.5 | 0.12 | 0.25 | 0.0 | 1.6 |
| All non-BI types | ≤0.06–1 | 0.12 | 0.25 | 0.0 | 1.8 | |
| A | ≤0.06–0.25 | 0.12 | 0.25 | 0.0 | 0.0 | |
| DH | ≤0.06–0.5 | 0.12 | 0.25 | 0.0 | 1.6 | |
| G | ≤0.06–0.25 | 0.12 | 0.12 | 0.0 | 0.0 | |
| Y | ≤0.06–1 | 0.12 | 0.25 | 0.0 | 1.8 | |
| Vancomycin | BI | ≤0.25–8 | 2 | 4 | NA | 29.3 |
| All non-BI types | ≤0.25–4 | 1 | 2 | NA | 7.5 | |
| A | 0.5–4 | 1 | 2 | NA | 7.1 | |
| DH | 0.5–4 | 1 | 4 | NA | 11.9 | |
| G | 0.5–4 | 1 | 2 | NA | 6.8 | |
| Y | 0.5–4 | 1 | 2 | NA | 4.3 | |
| Imipenem | BI | ≤0.12–16 | 8 | 8 | 7.4 | NA |
| All non-BI types | ≤0.12–16 | 4 | 8 | 3.9 | NA | |
| A | ≤0.12–16 | 4 | 8 | 2.4 | NA | |
| DH | 1–16 | 4 | 8 | 5.6 | NA | |
| G | 1–8 | 4 | 8 | 0.0 | NA | |
| Y | ≤0.12–16 | 4 | 8 | 3.7 | NA | |
| Moxifloxacin | BI | ≤0.5 to >16 | 16 | >16 | 84.0 | 84.0 |
| All non-BI types | ≤0.5 to >16 | 2 | 8 | 12.5 | 12.5 | |
| A | ≤0.5–16 | 2 | 2 | 4.8 | 4.8 | |
| DH | ≤0.5–16 | 2 | 2 | 5.6 | 5.6 | |
| G | ≤0.5 to >16 | 2 | 16 | 18.6 | 18.6 | |
| Y | ≤0.5 to >16 | 2 | 4 | 8.0 | 8.0 | |
| Metronidazole | BI | 0.12 to 4 | 2 | 2 | 0.0 | 7.4 |
| All non-BI types | ≤0.06–4 | 0.5 | 1 | 0.0 | 0.4 | |
| A | ≤0.06–2 | 0.5 | 1 | 0.0 | 0.0 | |
| DH | ≤0.06–2 | 0.5 | 1 | 0.0 | 0.0 | |
| G | 0.12–4 | 0.25 | 2 | 0.0 | 1.7 | |
| Y | ≤0.06–2 | 0.5 | 2 | 0.0 | 0.0 | |
| Clindamycin | BI | ≤0.5 to >16 | 4 | >16 | 48.4 | NA |
| All non-BI types | ≤0.5 to >16 | 4 | 16 | 23.5 | NA | |
| A | ≤0.5 to >16 | 4 | 8 | 16.7 | NA | |
| DH | ≤0.5 to >16 | 4 | 16 | 20.6 | NA | |
| G | ≤0.5–16 | 4 | 8 | 15.3 | NA | |
| Y | ≤0.5 to >16 | 4 | 8 | 17.2 | NA | |
| Chloramphenicol | BI | 1–16 | 4 | 8 | 0.0 | NA |
| All non-BI types | ≤0.5 to 16 | 4 | 8 | 0.0 | NA | |
| A | 1–8 | 4 | 8 | 0.0 | NA | |
| DH | 1–8 | 4 | 8 | 0.0 | NA | |
| G | 1–8 | 4 | 8 | 0.0 | NA | |
| Y | ≤0.5–8 | 4 | 8 | 0.0 | NA | |
a
All non-BI types includes the groups listed separately plus an additional 384 isolates from REA groups with <30 isolates.